OPKO Health, Inc. (OPK)

In the past six months, OPKO Health held a Q3 2025 financial results conference call on October 29, 2025, and participated in the Piper Sandler 37th Annual Healthcare Conference in December 2025 and the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company held a Q4 2025 financial results conference call on February 26, 2026, reporting a consolidated total revenue of $148.5 million and a net loss of $31.3 million. OPKO Health participated in the Jefferies Biotech on the Beach Summit on March 10-11, 2026. ModeX Therapeutics initiated a clinical trial of MDX2301 for COVID-19 prevention on April 8, 2026. OPKO Health and Entera Bio expanded their partnership to advance an oral long-acting PTH tablet for hypoparathyroidism on February 4, 2026. In Q4 2025, OPKO entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. As of April 11, 2026, analysts have given OPKO Health an average "Hold" recommendation. The share price as of April 9, 2026, was $1.17, representing a decline of 13.97% over the past year.

Explicit information regarding demand seasonality for OPKO Health's specific products and services was not found. Demand for pharmaceutical and diagnostic products can be less seasonal than consumer goods, driven more by disease prevalence, treatment guidelines, and healthcare access. Without specific data, it is not possible to definitively state the demand seasonality for OPKO Health's offerings.

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals, aiming to deliver next-generation solutions for serious diseases across global markets. The company operates within the Healthcare sector, including Drug Manufacturers, Medical Appliances & Equipment, and Biotechnology. Its business is structured around pharmaceuticals and diagnostics. Major products and services include Rayaldee for treating secondary hyperparathyroidism, NGENLA for pediatric growth failure, the 4Kscore Test for prostate cancer diagnosis, and pipeline therapies for cancer and infectious diseases through ModeX Therapeutics.

OPKO Health has a global reach with profitable operating businesses in the U.S., Mexico, Chile, Spain, Ireland, and Israel. Its therapies are sold worldwide through partnerships with companies like Pfizer and Merck. Its diagnostic operations, through BioReference Laboratories, extend into Latin America, serving customers in Mexico, Brazil, and Argentina.

OPKO Health's brand reputation has been influenced by advancements in its clinical pipeline, strategic collaborations, and the global commercialization of NGENLA. These include the initiation of a clinical trial for MDX2301 for COVID-19 prevention, partnerships with Regeneron Pharmaceuticals and Entera Bio, and the continued rollout of NGENLA in over 40 markets worldwide through its partnership with Pfizer. No significant negative events explicitly impacting OPKO Health's brand reputation were found within the past year.

OPKO Health, Inc. has 235 institutional owners and shareholders holding a total of 196,567,948 shares. Major institutional owners include Rubric Capital Management LP, BlackRock, Inc., and Vanguard Group Inc. Individuals hold approximately 48.68% of the shares, while institutions hold approximately 25.22% of the shares.